Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.

Robin Fackrell, Camille Carroll, Donald Grosset, Biju Mohamed, Papari Prashanth Reddy, Miriam Parry, Kallol Ray Chaudhuri, Thomas Foltynie

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)
45 Downloads (Pure)

Abstract

In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation catechol-O-methyl transferase inhibitor, and safinamide, a monoamine oxidase B inhibitor. This clinical consensus outlines the practical considerations relating to motor fluctuations and managing wearing-off in patients with PD, and provides a clinical insight to adjunctive treatment options, including opicapone and safinamide. Practice-based opinion was provided from a multidisciplinary steering Group of eight UK-based movement disorder and PD specialists, including neurologists, geriatricians and a nurse specialist, from England, Scotland and Wales.
Original languageEnglish
Pages (from-to)349-360
JournalNeurodegenerative Disease Management in Future Medicine
Publication statusPublished - 8 Oct 2018

Fingerprint

Dive into the research topics of 'Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.'. Together they form a unique fingerprint.

Cite this